Skyrizi (risankizumab-rzaa)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Prescription Required

  • Product Details


    Skyrizi, an interleukin-23 antagonist, is used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It's also used to treat adults with active psoriatic arthritis and moderately to severely active Crohn's disease.

    Skyrizi works to inhibit the release of chemicals that can cause inflammation.

    Skyrizi is available as a subcutaneous injection-to be injected underneath the skin. Patients may receive prefilled pens, prefilled syringes, or prefilled cartridges:

    • 150 mg/mL single-dose prefilled pen
    • 75 mg/0.83 mL single-dose prefilled syringe
    • 150 mg/mL single-dose prefilled syringe
    • 180 mg/1.2 mL single-dose prefilled cartridge
    • 360 mg/2.4 mL single-dose prefilled cartridge

    Fact Table




    US DailyMed, EU EMA, US FDA



    Legal status


    Chemical Name


    Elimination half-life

    approximately 28 days

    Dosage (Strength)

    150 mg/mL single-dose prefilled pen 75 mg/0.83 mL single-dose prefilled syringe 150 mg/mL single-dose prefilled syringe 180 mg/1.2 mL single-dose prefilled cartridge 360 mg/2.4 mL single-dose prefilled cartridge


    Consult doctor



    Protein binding


    PubChem CID





    Not Assigned

    ATC code






    Routes of administration

    Subcutaneous injection


    Use Skyrizi as directed by your doctor. If any questions or concerns arise, talk to your doctor or pharmacist.

    The dosage and duration of Skyrizi depends on the condition being treated. Your doctor will tell you how much Skyrizi should be administered and how long your treatment will last. Your doctor will also teach you how to properly inject Skyrizi.


    Skyrizi contains risankizumab-rzaa, a humanized immunoglobulin G1 monoclonal antibody. Inactive ingredients are also contained in each prefilled pen, syringe, and cartridge. Refer to the package insert for the full list of inactive ingredients.


    Patients who are allergic to risankizumab-rzaa or to any of its excipients should not use Skyrizi.


    • Before you begin treatment with Skyrizi, be sure to discuss the following with your doctor:
      • All the prescription and over-the-counter medications you take.
      • Your allergies.
      • Your past medical history and current health problems.
      • If you are pregnant or breastfeeding.
    • Skyrizi may cause serious allergic reactions, including anaphylaxis. Seek emergency care right away if you have trouble breathing, a rapid heart rate, a rash, or swelling of your lips, tongue, or throat.
    • Skyrizi can increase the risk of infection. Seek medical care right away if you develop any signs or symptoms of an infection.
    • Skyrizi should not be used in patients with active tuberculosis (TB) as the medication can cause TB activation.
    • Skyrizi can cause liver damage.
    • Live vaccines should not be given to patients who are being treated with Skyrizi.

    Side Effects

    Skyrizi medication side effects include upper respiratory infections, headache, fatigue, injection site reactions, joint pain, stomach pain, anemia, back pain, fever, joint problems, urinary tract infection, and fungal skin infections; however, these are not all the side effects that can be caused by Skyrizi. If you develop bothersome or persistent side effects, call your doctor right away.


    Skyrizi (risankizumab-rzaa). North Chicago, IL: AbbVie Inc.; 2022.

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 13816

  • Product Reviews


Please wait while the page is loading. Do not hit refresh or the browser back button to avoid any loss of information.

If you have any questions or concerns, please contact our Customer Service team via the chat option on our website or calling us toll free at: 1-800-891-0844